Once more Enantia will be present at the CPhI worldwide event, this year it will be held in Paris from October 5^th to 7^th. Visitors are kindly invited to drop by our stand (6K99) where we will be pleased to share with them how we can apply our chemical and solid form technologies and expertise to those R&D projects related with drug discovery and API chemical development. (July 9^th, 2010)

To be held in Pamplona from September 29th to October 1st, Enantia will be present in one of the most important events for the Spanish biotech sector. We will be pleased to share with you how we can contribute to your drug discovery and drug development projects, from medicinal chemistry support to the preparation of preclinical batches, including the optimization of the final solid form, we can be your end-to-end chemistry supplier. (July 9^th, 2010)

Set up on the basis of a strategic alliance between four pharmaceutical companies (Almirall, Esteve, Palau Pharma and Proteomika), the NEOGENIUS project will run for four years with a total budget of 15.4 million euros with the objective to discover and develop new painkilling medicines for patients suffering from osteoarthritis.

Enantia has been selected as custom synthesis provider to support the drug discovery activities of the consortium.

The history of NEOGENIUS as a consortium can be traced back to the GENIUS PHARMA project, a CENIT project approved in the first call for this programme in 2006 in which, in adition to Almirall, Esteve and Palau Pharma, other technological companies, among them, Enantia, also participated. GENIUS PHARMA attained its objective of consolidating different SMEs and PROs in Spain as technological platforms in different pharmaceutical research settings. In fact, NEOGENIUS’s external collaborations have been established with platforms from GENIUS PHARMA, which will provide this process with a high degree of inter-regionality and multidisciplinarity.

From March 8^th to 10^th Enantia will be attending BIO-Europe Spring 2010 in Barcelona. This partnering venue is ideal for interaction between the different players involved in the drug discovery arena. Therefore, we kindly invite all the participants to meet us there to discuss how we can contribute to their projects.

Effective December 23^rd, 2009, Enantia entered into the capital of Janus Developments along with two additional investors: the pharmaceutical group Ferrer Internacional and the financial institution Caixa Manresa. Following Enantia's strategy to be closer to the emerging biotech sector, we decided to tighten relations with the recently founded start-up Janus Developments by entering into its capital. More detailed information can be found in the article appeared in Diario Expansión on January 20^th, 2010.

From February 16th to 19th Enantia will be exhibiting at InformEx USA 2010 in San Francisco. We kindly invite you to visit our booth (1440) and discuss how we can contribute to your projects.

On November 3^rd, 2009 INNOBAIX was established as the commission to promote innovation and knowledge in the Baix Llobregat area. Enantia participates in this commission as a founder member along with other significant companies and organizations that put innovation at the forefront of their strategy. Innobaix will develop new collaboration networks, research programs and facilitate innovation processes between companies, universities and government agencies. In this way, Innobaix wants to foster entrepreneurship, open innovation, creativity and talent and become a reference for the development of a new economy in the area of Baix Llobregat.

From October 13^th to 15^th Enantia has been exhibiting at CPhI in Madrid. These have been hectic but fruitful days with the opportunity to meet with many customers to follow up existing projects, and the chance to discuss upcoming new opportunities. We want from here, to thank all those that dropped by for the fruitful discussions that we had and for interest shown in what we do.



 
 

From September 14^th to 16^th 2009, Enantia was exhibiting and participating in the yearly event that gathers the life science industry and leading CROs and CMOs from around the world. Taking place in Long Branch, NJ, USA, the venue was ideal for interaction between research services and manufacturing providers with a range of pharmaceutical and biotech companies, including many virtual biopharmaceutical organizations.

Enantia has been awarded the "Premis Pimec 2008" for the most competitive company in the category of small enterprises.The award was given personally to Mr. Llorenç Rafecas (CEO) by the King of Spain Juan Carlos I and the President de la Generalitat de Catalunya Mr. Jose Montilla during a ceremony that took place in Palau Sant Jordi, Barcelona on June 2^nd, 2008. This prize was a recognition of the competitiveness of Enantia, best shown by its high continuous growth since its foundation, its solid financial fundamentals and the level of innovation that it incorporates into its products and services.